NEW

2ND EPIC STUDY PUBLICATION

objective

The 2nd EPIC Study publication investigated the effect of pimobendan on clinical variables and the relationship between a change in heart size and the time to CHF or CRD in dogs with MMVD and cardiomegaly.1

study design1,2

  • Prospective, blinded study in dogs with Stage B2 MMVD. Dogs were randomised (1:1) to pimobendan or placebo groups
  • Relationships between short-term changes in echocardiographic variables and time to congestive heart failure (CHF)  or cardiac-related death (CRD) were explored at different time points:
AT DAY
Calendar 35 35
AND EVERY
Calendar 4 4
MONTHS*

findings

HEART SIZE ON DAY 35—LVIDDN Measurement

(Normalised left ventricular internal diameter in diastole)

VETMEDIN®

VETMEDIN® heart

Baseline-0.06 cm decreased

PLACEBO

PLACEBO heart

Baseline+0.01 cm increased

*P = <0.0001

Absolute Change From Baseline Median (Average)

* Between-group comparison (Mann-Whitney)

STUDY CONCLUSION

The 2nd EPIC Study publication findings further highlight the benefit of a proactive approach to preclinical MMVD. Results continue to support the case for early treatment of MMVD during Stage B2 to positively impact the life of dogs with MMVD.1

1-MONTH
IMPACT

Within the first month of pimobendan treatment, dogs demonstrated significant
decrease in heart size.

REDUCTION IN HEART SIZE

Observed heart size reduction was maintained over study duration, with dogs treated with pimobendan having a smaller average heart size.

MORE
TIME

In asymptomatic Stage B2
of heart disease*

Research studies support the link between increased heart size and increased risk of CHF and CRD.3-6

epic-study-results/dogs-icon-2nd-study

This site uses cookies to improve your browsing experience. By using this site, you agree to their use.

Cookie Information
welcome to EPICtrial.com
Disclaimer

Are you a resident of the United States of America?

INFORMATION DISCUSSED ON EPICTRIAL.COM RELATES TO AN INDICATION THAT IS NOT REGISTERED IN THE USA.

You will now be redirected to a USA-specific website.